[
  {
    "ts": "2025-11-10T09:00:00+00:00",
    "headline": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
    "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
    "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a7683f5d-6525-3fef-a31b-ff14cb1f8d54",
      "content": {
        "id": "a7683f5d-6525-3fef-a31b-ff14cb1f8d54",
        "contentType": "STORY",
        "title": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
        "description": "",
        "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
        "pubDate": "2025-11-10T09:00:00Z",
        "displayTime": "2025-11-10T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7",
          "originalWidth": 1045,
          "originalHeight": 364,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zXNKkkhZMap5mi1BfvNTKw--~B/aD0zNjQ7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7.cf.webp",
              "width": 1045,
              "height": 364,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1ZbnWrzrsTTPjuDyQZ978Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALVO"
            },
            {
              "symbol": "ALVOW"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:56:54+00:00",
    "headline": "Dupixent set for ninth US approval after Phase III AFRS success",
    "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
    "url": "https://www.clinicaltrialsarena.com/news/dupixent-set-for-ninth-us-approval-after-phase-iii-afrs-success/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "6c1d251e-ac2d-3c78-a721-7ac4f0b79223",
      "content": {
        "id": "6c1d251e-ac2d-3c78-a721-7ac4f0b79223",
        "contentType": "STORY",
        "title": "Dupixent set for ninth US approval after Phase III AFRS success",
        "description": "",
        "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
        "pubDate": "2025-11-10T11:56:54Z",
        "displayTime": "2025-11-10T11:56:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/dupixent-set-for-ninth-us-approval-after-phase-iii-afrs-success/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dupixent-set-ninth-us-approval-115654451.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T17:22:14+00:00",
    "headline": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
    "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
    "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "8a778143-1309-3481-8729-99aba2c721bc",
      "content": {
        "id": "8a778143-1309-3481-8729-99aba2c721bc",
        "contentType": "STORY",
        "title": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
        "description": "",
        "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
        "pubDate": "2025-11-10T17:22:14Z",
        "displayTime": "2025-11-10T17:22:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALVO"
            },
            {
              "symbol": "CBK.DE"
            },
            {
              "symbol": "BNP.PA"
            },
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T21:20:00+00:00",
    "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
    "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
    "url": "https://www.barrons.com/articles/mercks-heart-pill-cholesterol-stock-8be3690d?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8388595e-0aff-3659-9831-abe2edbce94f",
      "content": {
        "id": "8388595e-0aff-3659-9831-abe2edbce94f",
        "contentType": "STORY",
        "title": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
        "description": "",
        "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
        "pubDate": "2025-11-10T21:20:00Z",
        "displayTime": "2025-11-10T21:20:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8388595e-0aff-3659-9831-abe2edbce94f/merck%E2%80%99s-heart-pill-slashes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/d7855a853ab4a8287445ae3be33a812c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.C05mXQfhr7IGzf2qxHGiQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/d7855a853ab4a8287445ae3be33a812c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yFFgGmHyx9aTAK5_3z5iQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/d7855a853ab4a8287445ae3be33a812c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/mercks-heart-pill-cholesterol-stock-8be3690d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:25:05+00:00",
    "headline": "Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks",
    "summary": "Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finance.yahoo.com/news/winners-losers-q3-regeneron-nasdaq-092505823.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "dd942e51-1df0-3588-9a54-eccff0be1075",
      "content": {
        "id": "dd942e51-1df0-3588-9a54-eccff0be1075",
        "contentType": "STORY",
        "title": "Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks",
        "description": "",
        "summary": "Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.",
        "pubDate": "2025-11-10T09:25:05Z",
        "displayTime": "2025-11-10T09:25:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/winners-losers-q3-regeneron-nasdaq-092505823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/winners-losers-q3-regeneron-nasdaq-092505823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]